BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of $26.52 billion. The enterprise value is $10.59 billion.
Important Dates
The next estimated earnings date is Tuesday, May 5, 2026, before market open.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioNTech SE has 252.88 million shares outstanding. The number of shares has increased by 0.54% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 252.88M |
| Shares Change (YoY) | +0.54% |
| Shares Change (QoQ) | +2.02% |
| Owned by Insiders (%) | 16.73% |
| Owned by Institutions (%) | 20.43% |
| Float | 109.30M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 7.84 |
| Forward PS | 11.54 |
| PB Ratio | 1.15 |
| P/TBV Ratio | 1.30 |
| P/FCF Ratio | 79.88 |
| P/OCF Ratio | 49.33 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 32.04 |
Financial Position
The company has a current ratio of 7.54, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.54 |
| Quick Ratio | 6.87 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.95 |
| Interest Coverage | -89.20 |
Financial Efficiency
Return on equity (ROE) is -5.88% and return on invested capital (ROIC) is -25.47%.
| Return on Equity (ROE) | -5.88% |
| Return on Assets (ROA) | -3.56% |
| Return on Invested Capital (ROIC) | -25.47% |
| Return on Capital Employed (ROCE) | -6.38% |
| Weighted Average Cost of Capital (WACC) | 12.91% |
| Revenue Per Employee | $431,614 |
| Profits Per Employee | -$170,862 |
| Employee Count | 7,807 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 3.10 |
Taxes
In the past 12 months, BioNTech SE has paid $100.15 million in taxes.
| Income Tax | 100.15M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.02% in the last 52 weeks. The beta is 1.59, so BioNTech SE's price volatility has been higher than the market average.
| Beta (5Y) | 1.59 |
| 52-Week Price Change | +6.02% |
| 50-Day Moving Average | 98.33 |
| 200-Day Moving Average | 102.94 |
| Relative Strength Index (RSI) | 68.37 |
| Average Volume (20 Days) | 755,930 |
Short Selling Information
The latest short interest is 3.51 million, so 5.29% of the outstanding shares have been sold short.
| Short Interest | 3.51M |
| Short Previous Month | 3.54M |
| Short % of Shares Out | 5.29% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.29 |
Income Statement
In the last 12 months, BioNTech SE had revenue of $3.37 billion and -$1.33 billion in losses. Loss per share was -$5.52.
| Revenue | 3.37B |
| Gross Profit | 2.65B |
| Operating Income | -1.49B |
| Pretax Income | -1.23B |
| Net Income | -1.33B |
| EBITDA | -1.32B |
| EBIT | -1.49B |
| Loss Per Share | -$5.52 |
Full Income StatementBalance Sheet
The company has $16.13 billion in cash and $313.96 million in debt, with a net cash position of $15.82 billion or $62.56 per share.
| Cash & Cash Equivalents | 16.13B |
| Total Debt | 313.96M |
| Net Cash | 15.82B |
| Net Cash Per Share | $62.56 |
| Equity (Book Value) | 22.57B |
| Book Value Per Share | 89.81 |
| Working Capital | 16.44B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $535.40 million and capital expenditures -$205.59 million, giving a free cash flow of $330.67 million.
| Operating Cash Flow | 535.40M |
| Capital Expenditures | -205.59M |
| Depreciation & Amortization | 167.87M |
| Net Borrowing | -59.92M |
| Free Cash Flow | 330.67M |
| FCF Per Share | $1.31 |
Full Cash Flow StatementMargins
Gross margin is 78.70%, with operating and profit margins of -44.14% and -39.59%.
| Gross Margin | 78.70% |
| Operating Margin | -44.14% |
| Pretax Margin | -36.61% |
| Profit Margin | -39.59% |
| EBITDA Margin | -39.17% |
| EBIT Margin | -44.14% |
| FCF Margin | 9.81% |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.54% |
| Shareholder Yield | -0.54% |
| Earnings Yield | -5.05% |
| FCF Yield | 1.25% |
Dividend DetailsAnalyst Forecast
The average price target for BioNTech SE is $133.46, which is 27.26% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $133.46 |
| Price Target Difference | 27.26% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 5.47% |
| EPS Growth Forecast (5Y) | -19.33% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNTech SE has an Altman Z-Score of 6.72 and a Piotroski F-Score of 4.
| Altman Z-Score | 6.72 |
| Piotroski F-Score | 4 |
